Fast Five Quiz: Melanoma Treatment

Chih-Shan Jason Chen, MD, PhD


January 24, 2020

For patients with a high risk for relapse after surgical treatment, an anti–PD-1 agent or combination of agents is generally regarded as an appropriate first choice for adjuvant therapy. In patients with very low risk for relapse (≤ 10%), targeted therapy may be a more appropriate choice to avoid the modest potential for irreversible toxicity.

As noted in the European Consensus-based Interdisciplinary Guideline, early results of ongoing clinical trials with PD-1 antibodies in the adjuvant setting will be available in 2020.

The chemotherapeutic agent dacarbazine can be used for the treatment of metastatic melanoma. However, a randomized phase 3 trial of dacarbazine versus temozolomide showed the response rate was 12% versus 13%, respectively. On the basis of this trial and the greater ease of administration of temozolomide versus dacarbazine (oral versus intravenous), most oncologists prefer temozolomide as a first-line chemotherapy drug for melanoma.

Learn more about available adjuvant therapies for melanoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.